Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial

被引：10
|
作者：
Sonneveld, Pieter
Scheid, Christof
van der Holt, Bronno
el Jarari, Laila
Bertsch, Uta
Salwender, Hans
Zweegman, Sonja
Vellenga, Edo
Broyl, Annemiek
Blau, Igor Wolfgang
Weisel, Katja
Wittebol, Shulamit
Bos, Gerard M. J.
Stevens, Marjan
Schmidt-Wolf, Ingo G. H.
Pfreundschuh, Michael
Hose, Dirk
Jauch, Anna
van de Velde, Helgi
Raymakers, Reinier
Schaafsma, Martyn Ronald
Kersten, Marie Jose
Kooy, Marinus van Marwijk
Duehrsen, Ulrich
Lindemann, Hans Walter
Wijermans, Pierre W.
Lokhorst, Henk
Goldschmidt, H.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.404.404
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
404
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial
    Sonneveld, Pieter
    Salwender, Hans-Juergen
    Van der Holt, Bronno
    el Jarari, Laila
    Bertsch, Uta
    Blau, Igor W.
    Zweegman, Sonja
    Weisel, Katja C.
    Vellenga, Edo
    Pfreundschuh, Michael
    Broijl, Annemiek
    Scheid, Christof
    Wittebol, Shulamiet
    Bos, Gerard M. J.
    Stevens-Kroef, Marjan
    Jauch, Anna
    Potamianou, Anna
    Hose, Dirk
    Raymakers, Reinier
    Schaafsme, Marinus
    Kersten, Marie Jose
    Kooy, Marinus van Marwijk
    Duehrsen, Ulrich
    Lindemann, Hans Walter
    Brossart, Peter
    Wijermans, Pierre
    Lokhorst, Henk M.
    Goldschmidt, Hartmut
    BLOOD, 2015, 126 (23)
  • [2] Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/GMMG-HD4 Trial
    Sonneveld, Pieter
    Schmidt-Wolf, Ingo G. H.
    van der Holt, Bronno
    el Jarari, Laila
    Bertsch, Uta
    Salwender, Hans
    Zweegman, Sonja
    Vellenga, Edo
    Broyl, Annemiek
    Blau, Igor W.
    Weisel, Katja C.
    Wittebol, Shulamiet
    Bos, Gerard M. J.
    Stevens-Kroef, Marian
    Scheid, Christof
    Pfreundschuh, Michael
    Hose, Dirk
    Jauch, Anna
    van der Velde, Helgi
    Raymakers, Reinier
    Schaafsma, Martijn R.
    Kersten, Marie-Jose
    van Marwijk-Kooy, Marinus
    Duehrsen, Ulrich
    Lindemann, Walter
    Wijermans, Pierre W.
    Lokhorst, Henk M.
    Goldschmidt, Hartmut M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (24) : 2946 - 2955
  • [3] Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/GMMG-HD4 Trial (vol 30, pg 2946, 2012)
    Sonneveld, P.
    Schmidt-Wolf, I. G. H.
    van der Hold, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3654 - 3654
  • [4] Bortezomib during induction and maintenance before and after autologous transplantation improves overall survival in patients with renal impairment: subgroup analysis from the HOVON-65/GMMG-HD4 randomized trial for newly diagnosed multiple myeloma
    Scheid, C.
    Sonneveld, P.
    Schmidt-Wolf, I.
    van der Holt, B.
    Hielscher, T.
    el Jarari, L.
    Bertsch, U.
    Salwender, H.
    Zweegman, S.
    Haenel, M.
    Vellenga, E.
    Schubert, J.
    Blau, I. W.
    Jie, A.
    van de Velde, H.
    Peter, N.
    Schaafsma, M.
    Lindemann, W.
    Kersten, M.
    Duehrsen, U.
    Delforge, M.
    Weisel, K.
    Croockewit, S.
    Martin, H.
    Wittebol, S.
    Schouten, H.
    van Marwijk-Kooy, M.
    Wijermans, P.
    Lokhorst, H.
    Goldschmidt, H.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S37 - S38
  • [5] Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
    Broyl, Annemiek
    Corthals, Sophie L.
    Jongen, Joost L. M.
    van der Holt, Bronno
    Kuiper, Rowan
    de Knegt, Yvonne
    van Duin, Mark
    el Jarari, Laila
    Bertsch, Uta
    Lokhorst, Henk M.
    Durie, Brian G.
    Goldschmidt, Hartmut
    Sonneveld, Pieter
    LANCET ONCOLOGY, 2010, 11 (11): : 1057 - 1065
  • [6] Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma.
    Corthals, Sophie L.
    Goldschmidt, Hartmut
    Johnson, David C.
    Lokhorst, Henk
    de Knegt, Yvonne
    Zweegman, Sonja
    van der Holt, Bronno
    Hose, Dirk
    Kersten, Marie Jose
    Vellenga, Edo
    Durie, Brian G. M.
    Morgan, Gareth J.
    Sonneveld, Pieter
    BLOOD, 2009, 114 (22) : 712 - 712
  • [7] Bortezomib in induction and maintenance in multiple myeloma in forefront therapy: results of phase III HOVON-65/GMMG HD4
    Bonnet, Sarah
    Leleu, Xavier
    HEMATOLOGIE, 2012, 18 (06): : 307 - 308
  • [8] HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)
    Sonn-Eveld, Pieter
    Schmidt-Wolf, Ingo
    van der Holt, Bronno
    el Jarari, Laila
    Bertsch, Uta
    Salwender, Hans
    Zweegman, Sonja
    Vellenga, Edo
    Schubert, Joerg
    Blau, Igor Wolfgang
    Jie, Asiong
    Beverloo, Berna
    Hose, Dirk
    Jauch, Anna
    van de Velde, Helgi
    Schaafsma, Martijn
    Lindemann, Walter
    Kersten, Marie Jose
    Duehrsen, Ulrich
    Delforge, Michel
    Weisel, Katja
    Croockewit, Sandra
    Martin, Hans
    Wittebol, Shulamit
    Scheid, Christof
    Bos, Gerard
    van Marwijk-Kooy, Marinus
    Wijermans, Pierre
    Lokhorst, Henk
    Goldschmidt, Hartmut
    BLOOD, 2010, 116 (21) : 23 - 24
  • [9] Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial
    Mai, Elias K.
    Nogai, Axel
    Lokhorst, Henk M.
    van der Holt, Bronno
    Zweegman, Sonja
    Weisel, Katja C.
    Croockewit, Sandra
    Jauch, Anna
    Hillengass, Jens
    Stevens-Kroef, Marian
    Raab, Marc S.
    Broijl, Annemiek
    Bos, Gerard M. J.
    Brossart, Peter
    Ypma, Paula
    Hanoun, Christine
    Bertsch, Uta
    Hielscher, Thomas
    Salwender, Hans J.
    Scheid, Christoph
    Goldschmidt, Hartmut
    Sonneveld, Pieter
    HEMASPHERE, 2024, 8 (11):
  • [10] First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)
    Sonneveld, P.
    van der Holt, B.
    Schmidt-Wolf, I. G. H.
    Bertsch, U.
    el Jarari, L.
    Salwender, Hans-Juergen
    Zweegman, S.
    Vellenga, E.
    Schubert, J.
    Blau, I. W.
    Jie, G. S. K.
    Beverloo, B.
    Jauch, A.
    Hose, D.
    Schaafsma, R.
    Kersten, M. J.
    Delforge, M.
    de Weerdt, O.
    van der Griend, R.
    Wijermans, R. W.
    Martin, Hans
    van der Velde, H.
    Lokhorst, Henk M.
    Goldschmidt, H.
    BLOOD, 2008, 112 (11) : 243 - 244
12345